Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2018 Filed Dec 4, 2018 22:42 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $32.27 | $0.00 |
DisclosureSEC source: 0001177648-18-000051 · edgar.xml · derivative · entry 2 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 2,000 shares Expires 2024-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 22:42 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionCommon Stock | 2,000 | $32.27 | $64,540.00 |
DisclosureSEC source: 0001177648-18-000051 · edgar.xml · nonDerivative · entry 1 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:35 UTC |
Gardiner Nathaniel S.Sr. VP & General Counsel
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000050 · edgar.xml · derivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:22 UTC |
Ocain TimSenior Vice President
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000048 · edgar.xml · derivative · entry 1 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:13 UTC |
MELLETT PAUL JTreasurer and CFO
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000046 · edgar.xml · derivative · entry 1 MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:04 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000044 · edgar.xml · derivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 00:45 UTC |
Luly Jay R.Director · President and CEO
|
GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000040 · edgar.xml · derivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 00:57 UTC |
Or Yat SunSr. VP & CSO
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000042 · edgar.xml · derivative · entry 1 Or Yat Sun · CIK 0001571212 · Sr. VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $32.27 | $0.00 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · derivative · entry 8 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires 2024-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · derivative · entry 7 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
SaleCommon Stock | 604 | $85.30 | $51,520.90 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 6 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,127 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.915 to $85.67, inclusive. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
SaleCommon Stock | 14,677 | $84.02 | $1,233,113.11 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 5 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,731 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.77 to $84.73, inclusive. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
SaleCommon Stock | 6,219 | $83.47 | $519,127.29 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 4 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,408 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $82.77 to $83.76, inclusive. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
SaleCommon Stock | 3,500 | $82.04 | $287,142.10 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 3 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,627 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $81.84 to $82.21, inclusive. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionCommon Stock | 10,000 | $32.27 | $322,700.00 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 2 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:22 UTC |
Ocain TimSenior Vice President
|
Exercise / conversionCommon Stock | 15,000 | $19.98 | $299,700.00 |
DisclosureSEC source: 0001177648-18-000038 · edgar.xml · nonDerivative · entry 1 Ocain Tim · CIK 0001599020 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:20 UTC |
Gardiner Nathaniel S.Sr. VP & General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001177648-18-000036 · edgar.xml · derivative · entry 2 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,700 Underlying: Common Stock · 1,500 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:20 UTC |
Gardiner Nathaniel S.Sr. VP & General Counsel
|
Exercise / conversionCommon Stock | 1,500 | $34.70 | $52,050.00 |
DisclosureSEC source: 0001177648-18-000036 · edgar.xml · nonDerivative · entry 1 Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · derivative · entry 7 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,270 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 1,371 | $96.89 | $132,841.95 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $96.46 to $97.29, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 602 | $95.84 | $57,698.63 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.76 to $96.26, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 1,229 | $94.75 | $116,451.31 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $94.35 to $95.12, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 453 | $93.90 | $42,535.11 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.11, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 500 | $93.02 | $46,509.10 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.87 to $93.08, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,225 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 659 | $93.49 | $61,612.61 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.07 to $94.03, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 2,224 | $92.68 | $206,129.88 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.95, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 700 | $91.49 | $64,042.02 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,193 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $91.35 to $91.67, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 572 | $90.58 | $51,811.65 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.30 to $90.74, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:57 UTC |
Luly Jay R.Director · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,498 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001177648-18-000032 · edgar.xml · derivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,498 shares Expires 2022-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 20:57 UTC |
Luly Jay R.Director · President and CEO
|
Exercise / conversionCommon Stock | 8,498 | $11.77 | $99,990.02 |
DisclosureSEC source: 0001177648-18-000032 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,180 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 904 | $126.40 | $114,261.35 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 1,621 | $125.60 | $203,602.30 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,414 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 445 | $124.20 | $55,269.36 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,035 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 2,075 | $123.72 | $256,709.66 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,480 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 904 | $126.40 | $114,261.35 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 1,621 | $125.60 | $203,602.30 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 445 | $124.20 | $55,269.36 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,925 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 1,185 | $123.72 | $146,602.87 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · shares: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC |
Luly Jay R.Director · President and CEO
|
SaleCommon Stock | 4,125 | $127.12 | $524,379.08 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 5 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,026 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.80 to $127.52, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC |
Luly Jay R.Director · President and CEO
|
SaleCommon Stock | 7,738 | $126.36 | $977,787.61 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 4 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,151 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.79, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC |
Luly Jay R.Director · President and CEO
|
SaleCommon Stock | 7,538 | $125.27 | $944,264.91 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 3 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,889 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $125.79, inclusive. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 20:56 UTC |
Luly Jay R.Director · President and CEO
|
SaleCommon Stock | 12,622 | $124.26 | $1,568,460.21 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 2 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,427 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.74, inclusive. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 20:56 UTC |
Luly Jay R.Director · President and CEO
|
SaleCommon Stock | 2,977 | $123.81 | $368,567.78 |
DisclosureSEC source: 0001177648-18-000030 · edgar.xml · nonDerivative · entry 1 Luly Jay R. · CIK 0001571211 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.02, inclusive. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,135 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC |
Adda NathalieSr. VP & Chief Medical Officer
|
SaleCommon Stock | 658 | $115.89 | $76,253.91 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $115.65 to $116.08, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.